NYSE:STVNLife Sciences
Stevanato Group (STVN) Could Be 19% Undervalued As Alina Pen Approvals Expand In Europe
Stevanato Group (STVN) stock is in focus after the company reported that liraglutide combination products using its Alina 30 and Alina 50 pen injectors received marketing authorizations in multiple European countries.
See our latest analysis for Stevanato Group.
The Alina approvals come as Stevanato Group’s share price shows mixed momentum, with a 30 day share price return of 8.23% and a 90 day share price return of 12.08%. However, the year to date share price return is down 3.55% and the 1...